Blog

Latest news about encapsia

DIA 2019 - There's nothing quite like Encapsia

Written by Jon Carter, Product Manager
01 Aug 2019

What a week in San Diego at DIA 2019! After arriving home late (or early Friday morning) and exhausted from the long journey, I still have an energy coursing through my veins fuelled by the week we left behind. As I reflect what the week meant for us, I feel an excitement about the future of both Encapsia and our industry.

Having observed the conference themes and the offerings from other vendors, I can’t help but feel there is nothing quite like Encapsia. It is not only built for today’s trials, but also for tomorrow’s. One of the themes of the week was the exciting area of artificial intelligence. Encapsia leads the market with analytics capabilities that are already proven to support AI, by analyzing and populating data from CT scans directly into the CRF.

Themes from DIA in previous years, in my opinion, have never fully reached fruition. Have we completely implemented risk based monitoring? There has been some great work in the area, but EDC systems are typically not flexible enough to dynamically adjust SDV down to the datapoint level. Encapsia has no hard-wired SDV mode, but instead has fully configurable review modes that allow you to dynamically set and adjust what requires SDV or any other type of review!

Overall, I am hugely encouraged by what we have seen at DIA 2019. Firstly, the industry is heading in the right direction, and secondly, Encapsia is made for that direction. There really isn’t anything quite like Encapsia for the future of clinical trials.


Last 3 posts

Question: Your webinar presentation earlier this week was quite provocative. Could you tell us a bit more about your background? TCC: I started writing software and building computers from scratch from a very early age. My father and I ran an educational software company when I was a teenager, and then I went on to read Engineering and Computer Science at Oxford, capping this with a DPhil in AI before co-founding Cmed Technology - a lifetime writing, designing and creating enterprise platforms with a specialism and passion for the clinical trial space.
Cmed Technology announced today the encapsia Home Visit app is now available to capture and manage clinical trial data from patients at home or in the community. The app works seamlessly with all the other encapsia apps, including web EDC (Entry app) and direct data capture (esource app) to provide tremendous flexibility in the choice of data capture methods both before and during a study. This helps maintain patient participation and clinical data flow which is particularly compelling to minimize disruption during the COVID-19 pandemic as well as in the new landscape for clinical trials that is expected to follow.
The global COVID-19 crisis has fundamentally impacted the way we live our lives as well as the operation of the entire drug development community. During the early stages of the pandemic the Cmed leadership team has implemented a number of measures to ensure the safety of our employees, clients and partners, as well as ensuring the continued delivery of our CRO services and our encapsia clinical data system. Our goal has been to minimise the impact of COVID-19 on our business, our clients, investigator sites and patients.